Most cancers claims and specialty medication drive stop-loss price surge, QBE report finds
The annual report, which pulls on QBE's proprietary claims knowledge, discovered that neoplasms account for 36% of all stop-loss declare reimbursements, sustaining their place because the main analysis throughout all...








